Skip to main content
OpenTrials
Completed

NCT Number: NCT00532155

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic non-small cell lung cancer (NSCLC).

The secondary objectives were to compare other efficacy parameters, to assess the overall safety of the two treatment arms, to assess the pharmacokinetics of intravenous (IV) aflibercept in this participant population and to determine immunogenicity of IV aflibercept in all participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Non Small Cell Lung Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sanofi-Aventis Administrative Office, Buenos Aires, Argentina

Loading trial locations.

About this study

The study included:

  • A screening visit of up to 21 days prior to randomization
  • Randomization at baseline (Treatment was initiated with 3 days of randomization)
  • A treatment period with 3-week treatment cycles until the participant met the following discontinuation criteria: had progressive disease, had unacceptable toxicity, or refused further study treatment
  • A post study treatment follow-up period (a visit was scheduled every 8 weeks until death or end of study)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histological/cytological proven locally advanced or metastatic non-small cell lung cancer
  • Disease progression during or after one, and only one, prior anticancer therapy which is platinum-based for advanced or metastatic disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2
  • Adequate renal, liver and bone marrow functions

Exclusion criteria

  • Squamous histology/cytology
  • Less than 28 days elapsed from prior treatment with radiotherapy, surgery, or chemotherapy to the time of randomization
  • Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to > 25% of bone marrow
  • Prior docetaxel treatment
  • Uncontrolled hypertension

The above information was not intended to contain all considerations relevant to participation in a clinical trial.

Treatment and study plan

Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

Drug

6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.

Placebo

Drug

Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.

Docetaxel (Taxotere®)

Drug

75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.

Dexamethasone (pre- and post-medication for docetaxel)

Drug

As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Baseline to the date when 687 deaths occurred (26 January 2011)

    OS was time interval from the date of randomization to the date of death due to any cause. If death was not observed during the study, overall survival time was censored at the last date the participant was known to be alive, or the study cutoff date, whichever was earlier. The cut-off date for the OS was date when 687 deaths were observed.

    OS was estimated from Kaplan-Meier Curves.

Secondary outcomes

  1. Progression Free Survival (PFS)

    Time frame: Baseline to data cut-off (26 January 2011)

    PFS was defined as the time interval between the date of randomization and the time of occurrence of the first radiological tumor progression detected by a computer tomography (CT) scan and /or by Magnetic Resonance Imaging (MRI); or death due to any cause; whichever was earlier. Participants without disease progression were censored at the earliest date between their last valid tumour assessment and the data cutoff date.

    PFS was estimated from Kaplan-Meier Curves.

  2. Overall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria

    Time frame: Baseline to data cut-off (26 January 2011)

    Participants with OR were those who had a confirmed complete response [CR] or a confirmed partial response [PR], based on RECIST criteria, in which

    • CR refected the disappearance of all tumor lesions (with no new tumors)
    • PR reflected a pre-defined decrease in tumor burden - a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD
    • OR was CR + PR The response rate was the percent of participants with a response.

    To determine a response, tumors were assessed by the investigators using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks.

  3. Health Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS)

    Time frame: Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy.

    HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies (appetite, fatigue, cough, dyspnea, hemoptysis and pain), and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. The LCSS total score was defined as the mean of the 9 items of the scale, each scored between 0 (for best outcome) to 100 (for worst outcome).

  4. Health Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI)

    Time frame: Baseline (prior to first dose), at cycles 2 and 4 and at the end of study therapy.

    HRQL assessments were performed by participants using a self-administered LCSS questionnaire. LCSS is a 9-item questionnaire, six measuring major symptoms for lung malignancies, and 3 summation items related to total symptomatic distress, activity status and overall quality of life. Participant responses were measured using visual analogue scales (VAS) with 100-mm lines. ABSI was the mean score for the six major lung cancer symptoms (appetite, fatigue, cough, dyspnea, hemoptysis and pain), each scored between 0 (for best outcome) to 100 (for worst outcome).

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Collaborators

  • Regeneron Pharmaceuticals

Registry information

Official study title

A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Acronym: VITAL

Important dates

Study start
2007
Primary completion
2011
Study completion
2011
First posted
Sep 20, 2007
Registry last updated
Sep 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.